IRIS
SIMONELLI, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.073
AS - Asia 3.305
EU - Europa 1.438
SA - Sud America 762
AF - Africa 178
Continente sconosciuto - Info sul continente non disponibili 174
OC - Oceania 3
Totale 11.933
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.939
SG - Singapore 2.012
BR - Brasile 611
CN - Cina 514
IT - Italia 465
VN - Vietnam 321
FI - Finlandia 230
IE - Irlanda 163
DE - Germania 129
NG - Nigeria 117
HK - Hong Kong 103
FR - Francia 97
CA - Canada 81
SE - Svezia 75
GB - Regno Unito 73
IN - India 60
AR - Argentina 54
NL - Olanda 53
TR - Turchia 45
BD - Bangladesh 41
ID - Indonesia 32
IQ - Iraq 30
EC - Ecuador 27
PL - Polonia 27
IL - Israele 25
MX - Messico 21
RU - Federazione Russa 18
CL - Cile 17
JP - Giappone 17
BE - Belgio 16
ZA - Sudafrica 16
CO - Colombia 15
ES - Italia 15
VE - Venezuela 14
PK - Pakistan 13
UA - Ucraina 13
SA - Arabia Saudita 12
PY - Paraguay 11
MA - Marocco 10
AT - Austria 8
PH - Filippine 8
DZ - Algeria 7
EG - Egitto 7
MY - Malesia 7
TN - Tunisia 7
UY - Uruguay 7
UZ - Uzbekistan 7
CR - Costa Rica 6
JM - Giamaica 6
LT - Lituania 6
PT - Portogallo 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
KZ - Kazakistan 5
TW - Taiwan 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
EU - Europa 4
GE - Georgia 4
IR - Iran 4
KE - Kenya 4
LB - Libano 4
PE - Perù 4
AL - Albania 3
AU - Australia 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GT - Guatemala 3
HN - Honduras 3
HU - Ungheria 3
LV - Lettonia 3
NP - Nepal 3
PS - Palestinian Territory 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
CG - Congo 2
ET - Etiopia 2
GA - Gabon 2
GR - Grecia 2
HR - Croazia 2
JO - Giordania 2
KG - Kirghizistan 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
MK - Macedonia 2
NI - Nicaragua 2
OM - Oman 2
PA - Panama 2
AF - Afghanistan, Repubblica islamica di 1
AG - Antigua e Barbuda 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
Totale 11.748
Salva come PNG Salva come JPEG
Città #
Singapore 896
Wilmington 707
Chandler 508
Ashburn 461
Dallas 373
The Dalles 315
San Mateo 299
San Jose 280
Helsinki 229
New York 223
Milan 216
Shanghai 216
Ann Arbor 189
Council Bluffs 167
Dublin 163
Princeton 140
Lawrence 127
Beijing 125
Leawood 119
Benin City 117
Ho Chi Minh City 109
Hong Kong 100
Phoenix 85
Los Angeles 82
Woodbridge 81
Boardman 80
Paris 72
Santa Clara 68
Hanoi 67
Rome 62
São Paulo 62
Fairfield 60
Toronto 46
Amsterdam 43
London 38
Buffalo 36
Seattle 34
Kocaeli 29
Naples 26
Orem 23
Warsaw 22
San Diego 21
Figino 20
Chicago 19
Rio de Janeiro 18
Da Nang 16
Belo Horizonte 15
Brussels 15
Haiphong 15
Pune 15
Chennai 13
Atlanta 12
Boston 12
Norwalk 12
Baghdad 11
Guayaquil 11
Mexico City 11
Miami 11
Montreal 11
Porto Alegre 11
Tokyo 11
Charlotte 10
Erbil 10
Hillsboro 10
San Francisco 10
Brooklyn 9
Columbus 9
Curitiba 9
Denver 9
Manchester 9
Santiago 9
Stockholm 9
Abbiategrasso 8
Brasília 8
Dhaka 8
Monmouth Junction 8
Munich 8
Philadelphia 8
Falkenstein 7
Fortaleza 7
Johannesburg 7
Reston 7
Tashkent 7
Thái Nguyên 7
Baltimore 6
Biên Hòa 6
Buenos Aires 6
Cleveland 6
Detroit 6
Genoa 6
Goiânia 6
Guarulhos 6
Indpls 6
Jacksonville 6
Montevideo 6
Moscow 6
Nanjing 6
New Delhi 6
Oak Ridge 6
Quito 6
Totale 7.664
Salva come PNG Salva come JPEG
Nome #
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 146
MODULATION OF IL-2 CANCER IMMUNOTHERAPY BY CYCLOOXYGENASE (COX)-2 INHIBITORS: THERAPEUTIC AND BIOLOGICAL RESULTS OF IL-2 PLUS CELECOXIB IN METASTATIC RENAL CELL CANCER (RCC) PROGRESSING ON IL-2 ALONE 144
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy 135
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 135
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 130
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 129
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 128
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 125
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 125
Treatment of malignant pleural mesothelioma: current status and future directions 122
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 121
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 117
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 117
COVID-19 and liver cancer clinical trials: not everything is lost 115
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 112
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 108
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 108
Advances in the biology of malignant pleural mesothelioma 108
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 108
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 107
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 107
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 106
Reproducibility of the WHO classification of thymomas: practical implications 101
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 98
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 98
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 98
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 97
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 95
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 95
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 93
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 93
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 92
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 92
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 91
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 91
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 91
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 90
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 90
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 89
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 88
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 88
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 88
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 88
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 88
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 88
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 88
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 87
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 87
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 87
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 86
Neutrophils in Gliomas 86
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 86
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 85
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 85
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 84
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 84
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 84
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 83
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 83
Imaging biomarkers in primary brain tumours 82
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 81
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 81
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 81
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 81
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 80
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 79
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report 79
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 78
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 78
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events 77
Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study 77
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors 76
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome 76
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 76
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 76
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 76
Preoperative Diffusion Tensor Imaging and Neurite Dispersion and Density Imaging in Isocitrate Dehydrogenase-Mutant Grade 2 and 3 Gliomas: Definition of Tumor-Related Epilepsy and Predictive Factors of Seizure Outcomes Based on a Single-Center Retrospective Case Series 74
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 72
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 72
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes 72
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 71
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 71
Intensified chemotherapy with stem-cell rescue in germ-cell tumors 70
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey 70
Brain metastases and next-generation anticancer therapies: a survival guide for clinicians 70
Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions 69
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study 69
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 69
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study 69
First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer 69
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 68
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 67
Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future 67
Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study 66
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 66
Future developments in the management of malignant pleural mesothelioma 66
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 65
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 65
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 64
Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue 64
Totale 8.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022657 0 5 13 139 4 6 28 102 55 71 199 35
2022/20231.536 285 66 162 148 120 99 3 119 261 153 107 13
2023/20241.113 58 108 171 39 45 251 88 47 11 32 109 154
2024/20251.553 33 17 10 27 33 162 64 166 270 359 197 215
2025/20264.619 609 416 370 484 134 264 1.095 241 236 299 175 296
2026/2027953 617 336 0 0 0 0 0 0 0 0 0 0
Totale 11.933